Autoantibodies reactive to PEP08 are clinically related with morbidity and severity of interstitial lung disease in connective tissue diseases
-
- Maiko Okumura
- Department of Immunology Graduate School of Medicine and Pharmaceutical Sciences University of Toyama Toyama Japan
-
- Tatsuhiko Ozawa
- Department of Immunology Graduate School of Medicine and Pharmaceutical Sciences University of Toyama Toyama Japan
-
- Hiroshi Hamana
- Department of Immunology Graduate School of Medicine and Pharmaceutical Sciences University of Toyama Toyama Japan
-
- Yu Norimatsu
- Department of Immunology Graduate School of Medicine and Pharmaceutical Sciences University of Toyama Toyama Japan
-
- Reina Tsuda
- Department of Immunology Graduate School of Medicine and Pharmaceutical Sciences University of Toyama Toyama Japan
-
- Eiji Kobayashi
- Department of Immunology Graduate School of Medicine and Pharmaceutical Sciences University of Toyama Toyama Japan
-
- Koichiro Shinoda
- The First Department of Internal Medicine Graduate School of Medicine and Pharmaceutical Sciences University of Toyama Toyama Japan
-
- Hirofumi Taki
- The First Department of Internal Medicine Graduate School of Medicine and Pharmaceutical Sciences University of Toyama Toyama Japan
-
- Kazuyuki Tobe
- The First Department of Internal Medicine Graduate School of Medicine and Pharmaceutical Sciences University of Toyama Toyama Japan
-
- Johji Imura
- Department of Diagnostic Pathology Graduate School of Medicine and Pharmaceutical Sciences University of Toyama Toyama Japan
-
- Eiji Sugiyama
- Department of Clinical Immunology and Rheumatology Hiroshima University Hospital Minami Hiroshima Japan
-
- Hiroyuki Kishi
- Department of Immunology Graduate School of Medicine and Pharmaceutical Sciences University of Toyama Toyama Japan
-
- Atsushi Muraguchi
- Department of Immunology Graduate School of Medicine and Pharmaceutical Sciences University of Toyama Toyama Japan
Description
<jats:title>Abstract</jats:title><jats:p>Anti‐Ro52 autoantibodies (Ro52‐autoAbs) appear in the sera of connective tissue disease (CTD) patients with interstitial lung disease (ILD). Studies using patient sera have shown a correlation between the generation of Ro52‐autoAbs and the clinical morbidity and severity of CTD with ILD. In this study, we used a single B‐cell manipulating technology and obtained 12 different monoclonal Ro52‐autoAbs (mRo52‐autoAbs) from the selected four patients suffering from severe ILD with a high titer of Ro52‐autoAbs in their sera. Western blot analysis revealed that 11 of 12 mRo52‐autoAbs bound to the coiled‐coil domain of Ro52. Competitive ELISA demonstrated that mRo52‐autoAbs competed with each other to bind to Ro52. Epitope mapping showed that two of them specifically bound to a peptide (PEP08) in the coiled‐coil domain. We then examined the titer of Ro52‐autoAbs in the sera of 192 CTD patients and assessed the relationship between the serum levels of Ro52‐autoAbs that were reactive to PEP08 peptide and the clinical morbidity and severity of ILD. Statistical analysis revealed that the production of PEP08‐reactive Ro52‐autoAbs correlated with the morbidity and severity of ILD in CTD. Assessment of the production of PEP08‐reactive Ro52‐autoAbs in autoimmune diseases is useful for predicting the clinical morbidity of ILD.</jats:p>
Journal
-
- European Journal of Immunology
-
European Journal of Immunology 48 (10), 1717-1727, 2018-07-25
Wiley